Australia seems poised to gain access to a groundbreaking medication for excess weight: Retatrutide. This new dual molecule – acting on both GLP-1 and GIP receptors – shows significant efficacy in clinical studies, indicating substantial decreases in body fat. While availability hasn't occurred with Australian regulators, a number of people bat